MedTrace Logo

Assessment of Chemotherapy-induced Peripheral Neurotoxicity Using a Point-of-care Nerve Conduction Study Device

NCT04778878 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2025-08-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility of the Mediracer® NCS device in early detection of CIPN in patients receiving potentially neurotoxic substance (vincristine, oxaliplatin or docetaxel) as a part of their chemotherapy regimen.

Conditions

Interventions

DEVICE

Mediracer® NCS

A point-of-care, hand-held nerve conduction device

Sponsors & Collaborators

  • Oulu University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04778878 on ClinicalTrials.gov